Wound Healing, Senescence, and Senotherapeutics

Louise E. Pitcher; Elizabeth L. Schmidt

doi:10.1177/21621918261490101

ResearchHub

Search

Enriched record

Wound Healing, Senescence, and Senotherapeutics

Louise E. Pitcher, Elizabeth L. Schmidt

Advances in Wound Care2026doi:10.1177/21621918261490101

Citation graph

Abstract

Significance: Dermal repair is a tightly regulated process that becomes progressively impaired with aging, chronic diseases, and persistent tissue injury. Senescent cells (SnCs) accrue in the skin following damage and with advancing age, contributing to alterations in tissue homeostasis and repair. However, the role of SnCs in normal and impaired wound repair is pleiotropic and context-dependent, particularly in the context of age and chronic disease. Furthermore, the use of senotherapeutics that target SnCs can slow aging, mitigate chronic disease, and promote rejuvenation of aged tissues, implicating their potential efficacy in reverting dysregulated wound repair. Recent Advances: The implementation of multi-OMIC analysis examining SnCs has improved our understanding of SnC heterogeneity within the skin and identified distinct SnC subsets that differentially influence tissue repair and its dysfunction. These studies have facilitated the development of senotherapeutics that selectively eliminate SnCs or suppress their detrimental phenotype. Preclinical studies demonstrate that treatment with senotherapeutics can improve tissue integrity and restore regenerative capacity. Critical Issues: Despite significant progress, the types, functions, and temporal dynamics of SnC populations involved in wound healing remain poorly characterized. Further molecular and functional SnC phenotyping, especially under aged and diseased conditions, will be required to distinguish beneficial reparative senescence from persistent pathogenic senescence. In addition, optimal therapeutic timing, specificity, and delivery strategies remain unresolved. Paul D. Robbins Future Directions: Integrating multiomics approaches in preclinical and clinical studies will be required to distinguish beneficial transient senescence from persistent pathogenic senescence for the further development of SnC-targeting therapies.

Authors

Louise E. Pitcher#1 Elizabeth L. Schmidt#3

Institutions

No ROR-resolved institution is linked to this work yet.

Provenance

crossref

Confidence 100%

pubmed

Confidence 98%

europepmc

Confidence 96%

unpaywall

Confidence 95%

datacite

Confidence 0%

Referenced works

View all references →

No local reference links have been materialized yet.

Cited by

View all cited-by records →

No local citing links have been materialized yet.

External reference records

10.1038/sj.cdd.4401632

10.1002/adbi.202400090

10.1016/j.envpol.2024.123874

10.3390/biom13111614

10.1172/jci158450

10.3389/fcell.2020.00773

10.1016/j.cell.2022.11.001

10.1016/j.molmed.2024.05.012

10.1097/prs.0000000000009668

10.1159/000528271

10.1038/s41580-024-00715-1

10.1093/gerona/glt190

10.3389/fcell.2021.645593

10.1002/jemt.10249

10.1128/mcb.22.5.1352-1359.2002

10.1038/ncb2070

10.1182/blood-2009-12-257832

10.1038/nrc2440

10.3934/molsci.2016.3.300

10.1038/nrc1884

10.1016/j.cub.2017.07.033

10.1016/j.tcb.2022.04.011

10.1038/s43587-024-00755-4

10.1101/gad.290635.116

10.1111/acel.13052

10.1016/j.stem.2024.11.013

10.1016/j.devcel.2014.11.012

10.1111/jocd.70169

10.1089/rej.2022.0048

10.1111/jocd.16242

10.1152/physrev.00067.2017

10.1155/2016/9060143

10.3389/fbioe.2021.716184

10.3390/ijms19103217

10.1111/imr.12453

10.3390/ijms18071545

10.1161/01.res.0000209968.66606.10

10.3390/biology11121731

10.1098/rsob.200309

10.1016/j.tcb.2018.02.001

Additional external references

10.1016/j.biotechadv.2023.108169

10.1016/j.biotechadv.2023.108169 · doi-reference

10.1172/jci127692

10.1172/jci127692 · doi-reference

10.1016/j.celrep.2017.02.012

10.1016/j.celrep.2017.02.012 · doi-reference

10.1016/j.ebiom.2019.08.069

10.1016/j.ebiom.2019.08.069 · doi-reference

10.1111/joim.13141

10.1111/joim.13141 · doi-reference

10.1080/15384101.2017.1316573

10.1080/15384101.2017.1316573 · doi-reference

10.1007/s11357-019-00113-y

10.1007/s11357-019-00113-y · doi-reference

10.1111/wrr.13106

10.1111/wrr.13106 · doi-reference

10.3389/fonc.2019.01576

10.3389/fonc.2019.01576 · doi-reference

10.1111/acel.12344

10.1111/acel.12344 · doi-reference

10.1038/ncomms11190

10.1038/ncomms11190 · doi-reference

10.18632/aging.206165

10.18632/aging.206165 · doi-reference

10.1007/s10522-024-10103-z

10.1007/s10522-024-10103-z · doi-reference

10.1111/jdv.18051

10.1111/jdv.18051 · doi-reference

10.1038/s41467-022-32552-1

10.1038/s41467-022-32552-1 · doi-reference

10.1038/s41514-023-00109-1

10.1038/s41514-023-00109-1 · doi-reference

10.1016/j.ebiom.2018.09.015

10.1016/j.ebiom.2018.09.015 · doi-reference

10.1038/nrm.2017.68

10.1038/nrm.2017.68 · doi-reference

10.3389/fimmu.2019.00003

10.3389/fimmu.2019.00003 · doi-reference

10.15252/embj.2019101982

10.15252/embj.2019101982 · doi-reference

10.1111/acel.14358

10.1111/acel.14358 · doi-reference

10.1023/a:1021399228395

10.1023/a:1021399228395 · doi-reference

10.1111/acel.13845

10.1111/acel.13845 · doi-reference

10.3390/brainsci13030500

10.3390/brainsci13030500 · doi-reference

10.3389/fendo.2020.573032

10.3389/fendo.2020.573032 · doi-reference

10.1111/wrr.12952

10.1111/wrr.12952 · doi-reference

10.18632/aging.100423

10.18632/aging.100423 · doi-reference